Alpha lipoic acid administration improved both peripheral sensitivity to insulin and liver clearance of insulin reducing potential risk of diabetes and nonalcoholic fatty liver disease in overweight/obese PCOS patients

References

• Azziz R, Woods KS, Reyna R, et al. The prevalence and features of the polycystic ovary syndrome in an unselected population. J Clin Endocrinol Metab. 2004;89(6):2745–2749. doi:10.1210/jc.2003-032046.
   PubMed Web of Science ®Google Scholar
• Hahn S, Bering van Halteren W, Kimmig R, et al. Diagnostik des polycystischen ovarsyndroms/diagnostic procedures in polycystic ovary syndrome. J Lab Med. 2003;27(1-2):53–59. doi:10.1515/LabMed.2003.009.
   Google Scholar
• Fauser BC, Tarlatzis BC, Rebar RW, et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the amsterdam ESHRE/ASRM-Sponsored 3rd PCOS consensus workshop group. Fertil Steril. 2012;97(1):28–38.e25. doi:10.1016/j.fertnstert.2011.09.024.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Misso ML, Costello MF, International PCOS Network., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Hum Reprod. 2018;33(9):1602–1618. doi:10.1093/humrep/dey256.
   PubMed Web of Science ®Google Scholar
• Diamanti-Kandarakis E, Dunaif A. Insulin resistance and the polycystic ovary syndrome revisited: an update on mechanisms and implications. Endocr Rev. 2012;33(6):981–1030. doi:10.1210/er.2011-1034.
   PubMed Web of Science ®Google Scholar
• Teede HJ, Tay CT, Laven JJE, et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. J Clin Endocrinol Metab. 2023;108(10):2447–2469. doi:10.1210/clinem/dgad463.
   PubMedGoogle Scholar
• Zhao H, Zhang J, Cheng X, et al. Insulin resistance in polycystic ovary syndrome across various tissues: an updated review of pathogenesis, evaluation, and treatment. J Ovarian Res. 2023;16(1):9. doi:10.1186/s13048-022-01091-0.
   PubMed Web of Science ®Google Scholar
• Prati A, Genazzani AR, Genazzani AD. In Clinical Management of Infertility. Pathogenesis of PCOS: from metabolic and neuroendocrine implications to the choice of the therapeutic strategy. In: Genazzani AR, Ibáñez L, Milewicz A, Shah D, editors. Impact of polycystic ovary, metabolic syndrome and obesity on women health: volume 8: frontiers in gynecological endocrinology. Berlin/Heidelberg: Springer International Publishing; 2021. pp. 43–66.
   Google Scholar
• Srikanthan K, Feyh A, Visweshwar H, et al. Systematic review of metabolic syndrome biomarkers: a panel for early detection, management, and risk stratification in the west virginian population. Int J Med Sci. 2016;13(1):25–38. doi:10.7150/ijms.13800.
   PubMed Web of Science ®Google Scholar
• Pérez-Martínez P, Mikhailidis DP, Athyros VG, et al. Lifestyle recommendations for the prevention and management of metabolic syndrome: an international panel recommendation. Nutr Rev. 2017;75(5):307–326. doi:10.1093/nutrit/nux014.
   PubMed Web of Science ®Google Scholar
• Polyzos SA, Goulis DG, Kountouras J, et al. Non-alcoholic fatty liver disease in women with polycystic ovary syndrome: assessment of non-invasive indices predicting hepatic steatosis and fibrosis. Hormones. 2014;13(4):519–531.
   PubMedGoogle Scholar
• Utzschneider KM, Kahn SE, Polidori D. Hepatic insulin extraction in NAFLD is related to insulin resistance rather than liver fat content. J Clin Endocrinol Metab. 2019;104(5):1855–1865. doi:10.1210/jc.2018-01808.
   PubMed Web of Science ®Google Scholar
• Fosam A, Sikder S, Abel BS, et al. Reduced insulin clearance and insulin-degrading enzyme activity contribute to hyperinsulinemia in african americans. J Clin Endocrinol Metab. 2020;105(4):e1835–1846–e1846. doi:10.1210/clinem/dgaa070.
   Web of Science ®Google Scholar
• Genazzani AD, Prati A, Genazzani AR, et al. Synergistic effects of the integrative administration of acetyl-L-carnitine, L-carnitine, L-arginine and N-acetyl-cysteine on metabolic dynamics and on hepatic insulin extraction in overweight/obese patients with PCOS. Gynecol Reprod Endocrinol Metab. 2020;1(1):56–63.
   Google Scholar
• Genazzani AD, Battipaglia C, Semprini E, et al. Familial diabetes in obese PCOS predisposes individuals to compensatory hyperinsulinemia and insulin resistance (IR) also for reduced hepatic insulin extraction (HIE). Endocrines. 2022;3(2):296–302. doi:10.3390/endocrines3020024.
   Google Scholar
• Finucane FM, Sharp SJ, Hatunic M, et al. Liver fat accumulation is associated with reduced hepatic insulin extraction and beta cell dysfunction in healthy older individuals. Diabetol Metab Syndr. 2014;6(1):43. doi:10.1186/1758-5996-6-43.
   PubMedGoogle Scholar
• Leissring MA, González-Casimiro CM, Merino B, et al. Targeting insulin-degrading enzyme in insulin clearance. Int J Mol Sci. 2021;22(5):2235. doi:10.3390/ijms22052235.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Genazzani AR. Polycystic ovary syndrome as metabolic disease: new insights on insulin resistance. touchREV Endocrinol. 2023;19(1):71–77. doi:10.17925/EE.2023.19.1.71.
   PubMedGoogle Scholar
• Macut D, Božić-Antić I, Bjekić-Macut J, et al. Management of endocrine disease: polycystic ovary syndrome and nonalcoholic fatty liver disease. Eur J Endocrinol. 2017;177(3):R145–R158. doi:10.1530/EJE-16-1063.
   PubMedGoogle Scholar
• Macut D, Tziomalos K, Božić-Antić I, et al. Non-alcoholic fatty liver disease is associated with insulin resistance and lipid accumulation product in women with polycystic ovary syndrome. Hum Reprod. 2016;31(6):1347–1353. doi:10.1093/humrep/dew076.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Battipaglia C, Petrillo T, et al. HIE (hepatic insulin extraction) index in overweight/obese. PCOS patients with or without familial diabetes. Gynecol Reprod Endocrinol Metab. 2022;3(1):57–68.
   Google Scholar
• Genazzani AD, Shefer K, Della Casa D, et al. Modulatory effects of alpha-lipoic acid (ALA) administration on insulin sensitivity in obese PCOS patients. J Endocrinol Invest. 2018;41(5):583–590. doi:10.1007/s40618-017-0782-z.
   PubMed Web of Science ®Google Scholar
• Madeira IR, Carvalho CN, Gazolla FM, et al. [Cut-off point for homeostatic model assessment for insulin resistance (HOMA-IR) index established from receiver operating characteristic (ROC) curve in the detection of metabolic syndrome in overweight pre-pubertal children]. Arq Bras Endocrinol Metabol. 2008;52(9):1466–1473. doi:10.1590/s0004-27302008000900010.
   PubMedGoogle Scholar
• Genazzani AD, Prati A, Santagni S, et al. Differential insulin response to myo-inositol administration in obese polycystic ovary syndrome patients. Gynecol Endocrinol. 2012;28(12):969–973. doi:10.3109/09513590.2012.685205.
   PubMed Web of Science ®Google Scholar
• Genazzani AD, Petraglia F, Fabbri G, et al. Evidence of luteinizing hormone secretion in hypothalamic amenorrhea associated with weight loss. Fertil Steril. 1990;54(2):222–226. doi:10.1016/s0015-0282(16)53693-0.
   PubMed Web of Science ®Google Scholar
• Genazzani AD. Inositol as putative integrative treatment for PCOS. Reprod Biomed Online. 2016;33(6):770–780. doi:10.1016/j.rbmo.2016.08.024.
   PubMed Web of Science ®Google Scholar
• Genazzani AD. Expert’s opinion: integrative treatment with inositols and lipoic acid for insulin resistance of PCOS. Gynecol Reprod Endocrinol Metab. 2020;1(3):146–157.
   Google Scholar
• Genazzani AD, Prati A, Simoncini T, et al. Modulatory role of D-chiro-inositol and alpha lipoic acid combination on hormonal and metabolic parameters of overweight/obese PCOS patients. Euro Gynecol Obstet. 2019;1(1):29–33.
   Google Scholar
• Genazzani AD, Prati A, Marchini F, et al. Differential insulin response to oral glucose tolerance test (OGTT) in overweight/obese polycystic ovary syndrome patients undergoing to myo-inositol (MYO), alpha lipoic acid (ALA), or combination of both. Gynecol Endocrinol. 2019;35(12):1088–1093. doi:10.1080/09513590.2019.1640200.
   PubMed Web of Science ®Google Scholar
• Tura A, Ludvik B, Nolan JJ, et al. Insulin and C-peptide secretion and kinetics in humans: direct and model-based measurements during OGTT. Am J Physiol Endocrinol Metab. 2001;281(5):E966–E974. doi:10.1152/ajpendo.2001.281.5.E966.
   PubMed Web of Science ®Google Scholar
• Caumo A, Luzi L. First-phase insulin secretion: does it exist in real life! considerations on shape and function. Am J Physiol Endocrinol Metab. 2003;287(3):E371–E385. doi:10.1152/ajpendo.00139.2003.
   Web of Science ®Google Scholar
• Padmalayam I, Hasham S, Saxena U, et al. Lipoic acid synthase (LASY) a novel role in inflammation, mitochondrial function, and insulin resistance. Diabetes. 2009;58(3):600–608. doi:10.2337/db08-0473.
   PubMed Web of Science ®Google Scholar
• Laganà AS, Monti N, Fedeli V, et al. Does alpha-lipoic acid improve effects on polycystic ovary syndrome? Eur Rev Med Pharmacol Sci. 2022;26(4):1241–1247. doi:10.26355/eurrev_202202_28116.
   PubMed Web of Science ®Google Scholar
• Chalasani N, Younossi Z, Lavine JE, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American association for the study of liver diseases, American college of gastroenterology, and the American gastroenterological association. Hepatology. 2012;55(6):2005–2023. doi:10.1002/hep.25762.
   PubMed Web of Science ®Google Scholar
• Loria P, Adinolfi LE, Bellentani S, NAFLD Expert Committee of the Associazione Italiana per lo studio del Fegato., et al. Practice guidelines for the diagnosis and management of nonalcoholic fatty liver disease. A decalogue from the italian association for the study of the liver (AISF) expert committee. Dig Liver Dis. 2010;42(4):272–282. doi:10.1016/j.dld.2010.01.021.
   PubMedGoogle Scholar
• Bae JC, Rhee EJ, Lee WY, et al. Combined effect of nonalcoholic fatty liver disease and impaired fasting glucose on the development of type 2 diabetes. Diabetes Care. 2011;34(3):727–729. doi:10.2337/dc10-1991.
   PubMed Web of Science ®Google Scholar
• Jones H, Sprung VS, Pugh CJA, et al. Polycystic ovary syndrome with hyperandrogenism is characterized by an increased risk of hepatic steatosis compared to nonhyperandrogenic PCOS phenotypes and healthy controls, independent of obesity and insulin resistance. J Clin Endocrinol Metab. 2012;97(10):3709–3716. doi:10.1210/jc.2012-1382.
   PubMed Web of Science ®Google Scholar
• Birkenfeld AL, Shulman GI. Nonalcoholic fatty liver disease, hepatic insulin resistance, and type 2 diabetes. Hepatology. 2014;59(2):713–723. doi:10.1002/hep.26672.
   PubMed Web of Science ®Google Scholar